Wyeth has launched Torisel (temsirolimus), a first-line treatment for advanced renal cell carcinoma in patients with certain prognostic risk factors.

Temsirolimus is a selective inhibitor of mTOR (mammalian target of rapamycin). Inhibition of mTOR activity results in a G1 growth arrest in treated tumour cells resulting from selective disruption of translation of cell cycle regulatory proteins.

Torisel must be administrated under the supervision of a physician experienced in the use of antineoplastic medicinal products.

The recommended dose of temsirolimus for advanced renal cell carcinoma is 25mg by intravenous infusion given over a 30- to 60-minute period once weekly.

Treatment with Torisel should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs.

View Torisel drug record

Further information: Wyeth


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more